Napredna pretraga

Pregled bibliografske jedinice broj: 998065

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation


(AUGUSTUS trial) Lopes, RD; Heizer, G; Aronson, R; Vora, AN; Massaro, T; Mehran, R; Goodman, SG; Windecker, S; Darius, H; Li, J et al.
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation // The New England journal of medicine, 380 (2019), 16; 1509-1524 doi:10.1056/NEJMoa1817083 (međunarodna recenzija, članak, stručni)


Naslov
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

Autori
Lopes, RD ; Heizer, G ; Aronson, R ; Vora, AN ; Massaro, T ; Mehran, R ; Goodman, SG ; Windecker, S ; Darius, H ; Li, J ; Averkov, O ; Bahit, MC ; Berwanger, O ; Budaj, A ; Hijazi, Z ; Parkhomenko, A ; Sinnaeve, P ; Storey, RF ; Thiele, H ; Vinereanu, D ; Granger, CB ; Alexander, JH ; AUGUSTUS Investigators.

Kolaboracija
AUGUSTUS trial

Izvornik
The New England journal of medicine (0028-4793) 380 (2019), 16; 1509-1524

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni

Ključne riječi
Atrial fibrillation ; anticoagulant therapy ; acute coronary syndrome ; apixaban
(Atrial fibrillation ; anticoagulant therapy ; acute coronary syndrome ; apixabanary syndrome, apixaban)

Sažetak
Ppropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear. METHODS: In an international trial with a two-by-two factorial design, we randomly assigned patients with atrial fibrillation who had an acute coronary syndrome or had undergone PCI and were planning to take a P2Y12 inhibitor to receive apixaban or a vitamin K antagonist and to receive aspirin or matching placebo for 6 months. The primary outcome was major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and a composite of ischemic events. RESULTS: Enrollment included 4614 patients from 33 countries. There were no significant interactions between the two randomization factors on the primary or secondary outcomes. Major or clinically relevant nonmajor bleeding was noted in 10.5% of the patients receiving apixaban, as compared with 14.7% of those receiving a vitamin K antagonist (hazard ratio, 0.69 ; 95% confidence interval [CI], 0.58 to 0.81 ; P<0.001 for both noninferiority and superiority), and in 16.1% of the patients receiving aspirin, as compared with 9.0% of those receiving placebo (hazard ratio, 1.89 ; 95% CI, 1.59 to 2.24 ; P<0.001). Patients in the apixaban group had a lower incidence of death or hospitalization than those in the vitamin K antagonist group (23.5% vs. 27.4% ; hazard ratio, 0.83 ; 95% CI, 0.74 to 0.93 ; P = 0.002) and a similar incidence of ischemic events. Patients in the aspirin group had an incidence of death or hospitalization and of ischemic events that was similar to that in the placebo group. CONCLUSIONS: In patients with atrial fibrillation and a recent acute coronary syndrome or PCI treated with a P2Y12 inhibitor, an antithrombotic regimen that included apixaban, without aspirin, resulted in less bleeding and fewer hospitalizations without significant differences in the incidence of ischemic events than regimens that included a vitamin K antagonist, aspirin, or both. (Funded by Bristol-Myers Squibb and Pfizer ; AUGUSTUS ClinicalTrials.gov number, NCT02415400.).

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove
Klinički bolnički centar Osijek

Autor s matičnim brojem:
Kristina Selthofer-Relatić, (333024)

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati